PRF Technologies Ltd(PRFX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.28 | Insider Own | - | Shs Outstand | 0.0M | Perf Week | 2.13% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -17.43% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 13.27% | Short Float | - | Perf Quarter | -24.24% |
| Income | -0.01B | P/S | 79.19 | EPS this Y | - | Inst Trans | 0.19% | Short Ratio | 0.07 | Perf Half Y | -58.49% |
| Sales | 0.00B | P/B | 0.15 | EPS next 5Y | - | ROA | -35.16% | Short Interest | 0.02M | Perf YTD | -75.68% |
| Book/sh | 5.22 | P/C | 0.21 | EPS past 3/5Y | 80.39% 55.23% | ROE | -43.75% | 52W High | -90.18% ($7.95) | Perf Year | -88.09% |
| Cash/sh | 3.8 | P/FCF | - | Sales past 3/5Y | - | ROIC | -33.51% | 52W Low | 12.89% ($0.69) | Perf 3Y | -99.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.47% | Gross Margin | -3716.13% | Volatility(W/M) | 7.04% 5.96% | Perf 5Y | -99.97% |
| Dividend TTM | - | EV/Sales | -284.47 | Sales Y/Y TTM | - | Oper. Margin | -16629.03% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.07 | EPS Q/Q | -3.64% | Profit Margin | -17158.06% | RSI (14) | 42.15 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.07 | Sales Q/Q | - | SMA20 | -4.34% ($0.82) | Beta | 1.14 | Target Price | $240 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/3 | SMA50 | -13.85% ($0.91) | Rel Volume | 0.02 | Prev Close | $0.76 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -5.77% - | SMA200 | -58.11% ($1.86) | Avg Volume(3M) | 0.27M | Price | $0.78 |
| IPO | 2020/9/1 | Option/Short | No/Yes | Trades | 72 | Volume | 6,361 | Change | 2.85% |
💊 A drug delivery platform company. Developing anesthetics and ophthalmology drugs. Expanding into AI-powered solar analysis. Pursuing a diversification strategy. As of 2025, holds $0.1M in cash.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded less than usual. That is 2% of its average volume.
PRFX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $7,919. Peers typically go for $212.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.3%.
Tap to view numbers
It ranks #81 of 83 in the industry
Based on market cap of $2M.
RDHL#78 Redhill Biopharma Ltd ADR $4M PER - 
AKAN#79 Akanda Corp $3M PER - 
SXTC#80 China SXT Pharmaceuticals Inc $3M PER - PRFX#81 PRF Technologies Ltd $2M PER - 
SBFM#82 Sunshine Biopharma Inc $2M PER - 
FAQ
What kind of company is PRFX?
PRFX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PRFX?
The market cap of PRFX is approximately $2M, ranking 5,776 within its sector.
What is the 52-week high and low for PRFX?
PRFX has recorded a 52-week high of $7.95 and a low of $0.69.
